Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
Nozomu Yanaihara(Jikei University School of Medicine), Aikou Okamoto(Jikei University School of Medicine)
Cited by 15
Related Papers
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway
|Frontiers in Oncology|2024|13